• Working Hours - Mon - Thu: 8:00 - 17:00; Fri: 8:00 - 14:00
What are you looking for?

ONGOING PROJECTS

ONGOING PROJECTS

AFRICAN FEMALE BREAST CANCER EPIDEMIOLOGY

(LABORATORY SAFETY SCIENCE AND INNOVATION PROJECT)

We are a member of the PhArmacoVigilance Africa (PAVIA) consortium aimed at strengthening pharmacovigilance in four African countries namely Ethiopia, Nigeria, Swaziland and Tanzania. The consortium is funded by the European Developing Countries Clinical Trial Images Partnership (EDCTP).

To improve pharmacovigilance, the project is strengthening routine reporting of drug adverse events amongst other activities. We will also be carrying out research, training health care workers across the country on pharmacovigilance, and developing necessary guidelines.

The D2EFT study is a phase IIIB/IV randomised open-label trial to compare dolutegravir with pharmaco-enhanced darunavir versus dolutegravir with predetermined nucleosides versus recommended standard of care antiretroviral regimens in patients with HIV-1 infection who have failed recommended first line therapy.

The major aim of this study is to find the best 2nd line regimen, among the current range of drugs used in our environment that would have maximal benefit for most patients who have failed first line HIV 1 drugs.

This is without the infrastructure of drug sensitivity testing in a resource constrained environment. Its emphasis is finding a regimen that will fulfil criteria including:

  • Efficacy at significantly reducing viral load
  • Encouraging adherence due to a lower incidence of drug toxicity, drug to drug interactions or other adverse events,
  • Improving participant quality of life

The D2EFT study is designed to support HIV treatment in the sub-Saharan African context and will provide knowledge to significantly improve treatment outcomes and change the current strategy for managing patients who have failed 1st line HIV treatment.

This study is a cluster randomized trial of innovative interventions targeting challenges of adolescents in transitioning from the pediatric treatment to the adult treatment program. Specific aims are to,

  • Inform strategies for transitioning services in resource-limited settings
  • Examine developmental, clinical and other factors for successful transition
  • Gain insight on implementation barriers among African adolescents to inform targets for structured intervention.

ADAPT Study is an NIH R01 five-year study (2016-2021) conducted in central and Northern Nigeria at selected health facilities that we support with funding from US President’s Emergency Plan for AIDS Relief (PEPFAR) through CDC.

Building TRUST Study is a follow-on study to the TRUST study. TRUST study, an implementation science research grant, uncovered high-risk men who have sex with men (MSM) with a high HIV prevalence (44%) and low uptake of clinical care and treatment. These men also have low levels of disclosure of HIV and/or sexual orientation, high incidence rates of both HIV infection (13.9 per 100 person- years) and sexually transmitted infections (STI) (gonorrhea and chlamydia).

Building TRUST study suggests that there are interventions to address interpersonal, network and structural barriers to HIV treatment and prevention. It is framed in the 2014 WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations.  The aims the study include, investigating the impact of introducing Pre-exposure Prophylaxis (PrEP) and characterizing HIV transmission networks within the MSM community. This is to lead to interventions to prevent HIV transmission.

The goal of the Impact of Non-B HIV-1 Subtype on second-line Protease Inhibitor Regimens in Africa (INSPIRE) project is to identify factors that predict virological failure among patients with Protease Inhibitor (PI) containing regimens. These patients however, have no resistance using the conventional drug resistance testing assay, and are infected with wide range of HIV subtypes in Cameroon, Uganda, South Africa and Nigeria.  Findings from this study will provide further understanding on resistance to HIV drugs and inform National and International HIV/AIDS Treatment Guidelines.

Collaborators:  Miguel E. Quiñones-Mateu, Ph.D. Professor, Webster Family Chair in Viral Pathogenesis, Associate Dean Research, Department of Microbiology & Immunology, School of Biomedical Sciences

University of Otago, New Zealand

Bob Shafer, MD Division Infectious Diseases, Department Medicine, Stanford University, US

Eric O. Freed, PhD HIV Dynamics and Replication Program, NIH/NCI

This study examines awareness about Pre-Exposure Prophylaxis and willingness to use it among Men who have Sex with Men (MSM). The study, which is part of the PEPFAR Nigeria program to expand use of PrEP, has run from March 2017 till date.

Findings so far have shown that, prior discussion with healthcare workers about PrEP was significantly associated with increased PrEP awareness. Having a larger sexual network was associated with decreased PrEP awareness.  Also, feeling ashamed/embarrassed to use PrEP was associated with decreased willingness to use it. Most MSM in this cohort had no prior knowledge of PrEP. Perceived stigma associated with PrEP use may impact its uptake within this vulnerable community. Efforts, potentially through network interventions, are needed to educate and destigmatize PrEP use to reduce HIV transmission.

African Collaborative Center for Microbiome and Genomics Research (ACCME)

The African Collaborative Center for Microbiome and Genomics Research (ACCME) is a multi-institutional collaborative research funded by the National Institute of Health (NIH). It is a project that is being conducted to develop a better understanding of cervical cancer and the processes involved in the development of the disease. There are several members of this project and they are affiliated with different institutions. Click Here for more.

THE ADOLESCENT TO ADULT PATIENT CENTERED HIV TRANSITION STUDY

The FLEMING Fund is a UKaid Department of Health and Social Care programme helping to tackle anti-microbial resistance (AMR) in low- and medium-income countries around the world.

As part of the DAI Consortium, IHVN is providing technical support in the area of human health. Activities include carrying out needs assessment, biosafety/security assessment, and renovation of eighteen laboratories involved in the project.

The project is to strengthen systems for AMR surveillance across human, animal and environmental health sectors as part of One Health.

(NIGERIAN POPULATION-BASED HIV IMPACT ASSESSMENT)

The BEAMING Study is researching into how breast milk affects infant’s gut bacteria and how this in turn affects infant’s growth and their ability to respond to childhood vaccination. This effect will be studied in HIV exposed uninfected children and the results compared with HIV uninfected unexposed children.

It is an NIH funded study that will utilize stored samples from HIV-Exposed Infants in a previous study, the Infant Study.

This study seeks to evaluate the prevalence of malaria parasitemia among blood donors donating blood to children 0-10 years in Abuja, Nigeria. It is funded by the International Society for Blood Transfusion.

This study conducts rigorous research into breast cancer and its molecular subtypes in indigenous population of Nigeria, in order to understand the epidemiological and genomic determinants of the incidence of breast cancer, its molecular subtypes, and the role of diet in etiology of breast cancer in Nigeria.

The TRACING study is a prospective cohort study that is made up of two components. The first component seeks to train health care workers on tuberculosis infection control practices, assess the level of infection control, and measure the output of these trainings. The second component of the study seeks to measure the risk of tuberculosis infections among health care workers.

Aim of the study is to provide evidence to strengthen TB infection control mechanism, and develop policies relevant for protecting health workers.

It is being implemented in at least 14 health facilities across the Federal Capital Territory and Nasarawa States. Facilities were selected based on the availability of HIV and TB services, and the number of patients accessing care in these facilities.

The project uses the Oxford Nanopore, a USB-sized, portable sequencing instrument, to develop a diagnostic assay. This assay rapidly diagnoses patients with acute febrile illness by screening for all potential pathogens in under two hours.

The goal of this five year project is implementation of a field-ready, real-time sequencing assay for unbiased pathogen diagnosis of acute febrile illness using metagenomic nanopore sequencing.

This project is a partnership between Africa Centers for Disease Control and Resolve to Save Lives (RTSL) initiative which is part of Vital Strategies. The initiative is aimed at improving the capacity and preparedness of Low-and Medium-Income countries to prevent disease outbreaks.

We are a sub-grantee to Vital Strategies in this project. Our mandate is to strengthen and expand existing national and regional laboratory systems and networks. In collaboration with the Nigeria Center for Disease Control, we are building the capacity of six yellow fever network laboratories as part of fostering national ownership of the process.

These laboratories are; National Reference Laboratory Gaduwa, Abuja, Central Public Health Laboratory, Lagos; Maitama District Hospital, Abuja; Yusuf Dantsoho Hospital, Kaduna; University of Nigeria Teaching Hospital, Enugu and University of Benin Teaching Hospital, Benin.

Close Bitnami banner
Bitnami